Johnson & Johnson (J&J) resumes roll-out of COVID-19 vaccine in EU

This follows confirmation from the EMA’s Pharmacovigilance Risk Assessment Committee of its overall benefit-risk profile, although J&J must update the product information to include mention that very rare blood clots in combination with low platelet counts have been reported.

Source:

PharmaTimes